Eli Lilly and Company (NYSE:LLY) SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the sale, the senior vice president now owns 54,885 shares in the company, valued at $4,729,989.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Eli Lilly and Company (NYSE:LLY) opened at $85.32 on Thursday. The stock has a market capitalization of $94,231.72, a PE ratio of 20.92, a price-to-earnings-growth ratio of 1.88 and a beta of 0.35. Eli Lilly and Company has a twelve month low of $66.39 and a twelve month high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter last year, the company posted $0.88 earnings per share. The business’s revenue was up 9.0% on a year-over-year basis. sell-side analysts forecast that Eli Lilly and Company will post 4.21 EPS for the current year.
LLY has been the topic of a number of analyst reports. BMO Capital Markets restated a “sell” rating and issued a $73.00 price target on shares of Eli Lilly and in a research note on Wednesday, August 16th. BidaskClub lowered Eli Lilly and from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Jefferies Group reaffirmed a “buy” rating and set a $89.00 price objective (down previously from $94.00) on shares of Eli Lilly and in a report on Thursday, August 24th. Leerink Swann reaffirmed a “hold” rating on shares of Eli Lilly and in a report on Thursday, August 31st. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a report on Thursday, August 31st. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $90.25.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC purchased a new position in shares of Eli Lilly and during the third quarter worth about $916,000. Public Employees Retirement System of Ohio grew its holdings in shares of Eli Lilly and by 0.4% during the third quarter. Public Employees Retirement System of Ohio now owns 684,533 shares of the company’s stock worth $58,555,000 after buying an additional 2,452 shares during the last quarter. Garde Capital Inc. purchased a new position in shares of Eli Lilly and during the third quarter worth about $202,000. Archford Capital Strategies LLC grew its holdings in shares of Eli Lilly and by 26.2% during the third quarter. Archford Capital Strategies LLC now owns 8,076 shares of the company’s stock worth $690,000 after buying an additional 1,676 shares during the last quarter. Finally, Salem Investment Counselors Inc. lifted its position in Eli Lilly and by 7.5% in the third quarter. Salem Investment Counselors Inc. now owns 48,460 shares of the company’s stock valued at $4,173,000 after purchasing an additional 3,400 shares during the period. 76.43% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.